Purpose: Perineural invasion (PNI) on needle prostatic biopsies (NPB) has been controversial as a marker of extraprostatic extension and consequently for planning of nerve-sparing radical prostatectomy (RP). The aim of this study was to find whether tumor extent on NPB influences the value of PNI to predict stage > pT2 on RP. Materials and Methods: This retrospective study was based on 264 consecutive patients submitted to radical retropubic prostatectomy. Their NPB were matched with whole-mount processed and totally embedded surgical specimens. Tumor extent on NPB was evaluated as the percentage of linear tissue in mm containing carcinoma in all cores. Considering the median value, patients were stratified into 2 groups: harboring less or more extensive tumors on NPB. Univariate and multivariate logistic regression analyses were used to relate stage > pT2 to PNI and other clinical and pathological variables. Results: In patients with more extensive tumors, PNI was predictive of stage > pT2 in univariate analysis but not in multivariate analysis. In less extensive tumors, PNI showed no association between any clinical or pathological variables studied; no difference in the time to biochemical progression-free status compared to patients without PNI; and, no predictive value for pathological stage > pT2 on both univariate and multivariate analyses. Conclusion: Tumor extent on NPB influences the predictive value of PNI for pathologic stage > pT2 on RP. With a higher number of small tumors currently detected, there is no evidence that perineural invasion should influence the decision on preservation of the nerve during radical prostatectomy.
INTRODUCTION
Perineural invasion (PNI) on needle prostatic biopsies as a marker of extraprostatic extension has been controversial (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In almost all studies, perineural invasion has been related to extraprostatic extension in univariate analysis but in only a few Clinical Urology Clinical Urology doi: 10.1590/S1677-55382010000400007 studies in multivariate analysis. The practical importance relates to the decision of whether to sacrifice part or all of the neurovascular bundle on the side of the biopsy with PNI when planning nerve-sparing radical prostatectomy. The aim of this study was to determine whether tumor extent on needle biopsies significantly influences the value of PNI to predict stage > pT2 (pT3a and/or pT3b) on radical prostatectomies.
MATERIALS AND METHODS
This retrospective study was based on 264 consecutive patients submitted to radical retropubic prostatectomy by one surgeon (UF) in the period 1997 to 2008 due to clinically localized (T1c or T2) prostate adenocarcinoma. Their needle prostatic biopsies (mean 9 cores per biopsy) were matched with whole-mount processed and totally embedded surgical specimens. A mean of 32 paraffin blocks were processed, and 6μm sections from each block were stained with hematoxylin and eosin. PNI was considered as prostate cancer extension along the perineural sheath ( Figure-1 ). The presence of any PNI, regardless of amount, was recorded as positive for PNI. Positive surgical margins were defined as cancer cells touching the inked surface of the prostate. Extraprostatic extension (pT3a) was diagnosed whenever cancer was seen in adipose tissue and, in case of desmoplastic response, whenever a protuberance corresponding to extension of tumor into the periprostatic tissue was seen (16) . Seminal vesicle invasion (pT3b) was defined as invasion of the muscular wall (17) .
Extent on needle biopsy was evaluated as the percentage of linear tissue in mm containing carcinoma. Considering the median value of extent, biopsies were stratified into 2 equal groups: 132 biopsies with less extensive and 132 biopsies with more extensive tumors. Tumor extent on radical prostatectomy was estimated by use of a point-count method previously described (18, 19) . Grading was according to the standard Gleason system (20, 21) . All pathological findings were evaluated by one senior uropathologist (AB).
Clinical variables analyzed included preoperative serum prostate-specific antigen (PSA), age and clinical stage (T1c or T2). Total serum PSA was measured utilizing previous validated Immulite® PSA kit. Biochemical progression was defined as PSA ≥ 0.2 ng/mL according to recommendation of the American Urological Association (22) . After radical prostatectomy, serum PSA was drawn every 3 months during the first year, every 6 months during the second year, and annually thereafter. The mean and median followup of the patients was 28 and 20 months, respectively. No patient of this series was treated before or after surgery.
The data were analyzed using the MannWhitney test for comparison of means and the Fishers exact test for comparison of proportions. Time to biochemical (PSA) progression-free outcome was studied using the Kaplan-Meier product-limit analysis; the comparison between the groups was done using the Log-rank test. Univariate and multivariate analyses using a logistic regression model was used to relate the outcomes of prostatectomy stage > pT2 to several clinical and pathological variables. Two-sided P value < 0.05 was considered statistically significant. All statistical analyses were performed using the commercially available SPSS 15.0. Table-1 shows the clinical and pathological findings of the 264 patients studied. Perineural invasion was present in 48/264 (18.2%) biopsies. The median value of tumor extent on biopsy was 13.6%. The frequency of PNI in the group with less extent tumors (≤ 13.6% of tissue in mm containing carcinoma) was 10.6%; in the group with more extensive tumors (> 13.6% of tissue in mm containing carcinoma) the frequency of PNI was 25.8%. Figures-2 and 3 show the Kaplan-Meier biochemical progression-free survival curve following radical prostatectomy. In patients with less extensive tumors on biopsy ( Figure- 2), at 5 years, 71% of the patients without PNI were free of biochemical progression compared to 83% of the patients with PNI. There was no statistically significant difference between the groups (log-rank, p = 0.24). In patients with more extensive tumors on biopsy ( Figure- 3), at 5 years, 43% of the patients without PNI were free of biochemical progression compared to 33% of the patients with PNI. There was no statistically significant difference between the groups (Log-rank, p = 0.26). Table-3 shows the univariate and multivariate logistic regression analyses of several clinical and pathological variables predictive of pathological stage > T2 on radical prostatectomy in patients with less extensive tumors on biopsy. PNI was not predictive of stage > pT2 on both analyses. On univariate analysis, only extent of cancer and Gleason score on biopsy were predictive. On multivariate analysis, extent of tumor on biopsy was statistically significant and Gleason score on the level of significance. Table-4 shows the univariate and multivariate logistic regression analyses of several clinical and pathological variables predictive of pathological stage > T2 on radical prostatectomy in patients with more extensive tumors on biopsy. PNI was predictive of stage > pT2 only on univariate analysis. Other variables statistically significant on univariate analysis were preoperative PSA, tumor extent on needle biopsy, and Gleason score on biopsy. On multivariate analysis, only extent of tumor on needle biopsy was an independent predictor of stage > pT2 (pT3a and/or pT3b) on radical prostatectomy.
RESULTS

COMMENTS
Our study showed that extent of tumor influences the value of PNI to predict pathological stage (1) 0.20 (1) Clinical stage 0.47 (2) 0.66 (2) Preoperative PSA 0.36 (1) 0.14 (1) Gleason score on needle biopsy 0.79 (1) 0.02 (1) Tumor extent on radical prostatectomy 0.13 (1) 0.09 (1) Positive margins 0.23 (2) 0.16 (2) Extraprostatic extension 0.43 (2) 0.02 (2) Seminal vesicle invasion 0.24 (2) 0.04 (2) ( > T2 on radical prostatectomies. In patients with less extensive tumors on biopsy (≤ 13.6% of tissue in mm containing carcinoma) and PNI, there was no association to any one clinical or pathological variable studied; no difference in the time to biochemical (PSA) progression-free outcome compared to patients without PNI; and, no predictive value for pathological stage > pT2 on both univariate and multivariate analysis. The only study to mention the influence of extent of tumor to the predictive value of PNI is Rubins's et al. (6) . In their study, PNI revealed a significant association with stage pT3 on univariate analysis. However, on multivariate analysis the association was significant only when the greatest percentage of any single biopsy involved by prostate carcinoma and the total percentage of cancer in all cores were not considered, due to a significant interaction between these measures and PNI. The findings with more extensive tumors on biopsy are in accordance with most of the studies in the literature. Egan and Bostwick (2) found on univariate analysis that PNI on needle biopsy was significantly associated to extraprostatic extension and seminal vesicle invasion. On multivariate analysis, however, only preoperative PSA, proportion of the biopsy involved by cancer, and Gleason score were significant. Ukimura et al. (4) found that PNI on biopsy was a good predictor among others studied for extraprostatic extension on univariate analysis but not on multivariate analysis. In the study by Vargas et al. was not an independent predictor of either adverse pathology or biochemical failure. In Bismar's et al. study (11) neither presence nor absence of perineural nor number nor percentage of positive nerves were related to pathologic stage on univariate or multivariate analyses. In Tsuzuki's et al. study (12) PSA, Gleason score, digital rectal examination, percent of side specific cores with tumor and average percent involvement of each positive core but not PNI were found to be statistically significant independent predictors of extraprostatic extension in the region of the neurovascular bundle. Studying 452 consecutive patients undergoing radical retropubic prostatectomy by a single surgeon, Cannon et al. (13) concluded that although biopsy PNI alone was associated with a higher probability of extraprostatic extension, it was not predictive of bilateral nervesparing technique or a positive surgical margin in an individual patient.
1) Mann-Whitney test; (2) Fisher's exact test
In other studies, however, PNI was an independent predictor of final pathologic stage. de la Taille et al. (3) found that PNI, PSA and Gleason score on the biopsy independently predicted stage pT3 disease. The authors concluded that PNI is an important preoperative predictor of pathologic stage and should be reported when adenocarcinoma is diagnosed on prostate needle biopsies. In the Sebo et al. study (8) joint predictors of extraprostatic exten-sion were the percent cores positive for carcinoma, Gleason score of 7, Gleason score of 8 or 9, serum PSA and PNI. In the Loeb et al. study (15) , PNI was significantly associated with aggressive pathology and biochemical progression. On multivariate analysis, PNI was significantly associated with extraprostatic extension and seminal vesicle invasion. Bastacky et al. (1) studied 302 needle prostatic biopsies and found a sensitivity of 27% and a specificity of 96% for PNI to predict extraprostatic extension. They concluded that measuring PNI on needle biopsy helps identify extraprostatic extension and may help in planning nerve-sparing radical prostatectomy in the decision of whether to sacrifice part or all of the neurovascular bundle on the side of the biopsy. These authors did not study the predictive value on multivariate analysis.
Some factors may be responsible for the discrepancies in the literature: the number of cores examined per case may influence the rate of detection of PNI, the different methods of processing and submitting tissue from radical prostatectomy specimens (completely vs. partially embedded prostate glands) may contribute to different rates of detection of extraprostatic carcinoma, different definitions of PNI on needle biopsy tissue and extraprostatic extension, and different values of PSA for evaluation of biochemical progression-free outcome following surgery. In a search from January 1990 to December 2005 using MEDLINE, Embase, and the Web of Knowledge, Harnden et al. (14) performed a systematic review of studies that examined the association between perineural invasion and prostate cancer recurrence. These authors concluded that a considerable variation in study design, execution, and reporting precluded meta-analysis and quantitative risk estimation.
The frequency of perineural invasion on needle prostatic biopsies varies from 11% to 38% (1) (2) (3) (4) (5) (6) 8, 10, 11) . Considering all biopsies in our study the frequency was 18%. In the group with less extensive tumors the frequency was 10.6% and in the group with more extensive tumors 25.8%. It is worth noting that in less extensive tumors the frequency of PNI is in the lower range of the frequency found in the literature. Studying very small tumors on biopsies (less than 1 mm in length in only one core), Thorson et al. (23) still found a frequency of 2% of PNI. We have also seen PNI invasion in autopsied patients with very small incidentally found histologic carcinomas. These findings probably suggest that PNI may be an early event. This suggestion is shared by Byar and Mostofi (24) . The authors studied 208 total prostates removed using the step-section technique for early carcinoma of the prostate. The high frequency of PNI found (84.1%) suggested by the authors that the phenomenon occurs early in the course of the disease. The similarity in the survival rates for cases with and without PNI indicated little if any prognostic significance.
Our study may have some limitations. All patients were submitted to radical prostatectomy, and therefore we were unable to determine any different effect of PNI on biochemical progression-free outcome with other forms of treatment, such as watchful waiting or radiotherapy. Another limitation could be related to the fact that we only recorded the presence or absence of PNI on needle biopsy but did not quantify the extent. In addition, the mean follow-up is relatively short, and it is possible that greater differences could occur with additional follow-up. A strength of the study could be the homogeneity of the study population which was comprised of consecutive patients treated by one expert surgeon limiting any influence of variability in surgical technique and the pathological evaluation also by one senior uropathologist.
In summary, tumor extent on needle biopsies influences the predictive value of PNI for pathologic stage > pT2 (pT3a and/or pT3b) on radical prostatectomies. In patients with more extensive tumors on needle biopsy, PNI predicted pathologic stage > pT2 on radical prostatectomy on univariate analysis but on multivariate analysis did not show independent predictive value. This finding is in accordance to most of the studies reported in the literature. In patients with less extensive tumors on biopsy (≤ 13.6% of tissue in mm containing carcinoma) and PNI, there was no association between any clinical or pathological variables studied; no difference in the time to biochemical (PSA) progression-free outcome comparing to patients without PNI; and, no predictive value for pathological stage > pT2 on both univariate and multivariate analysis. With a higher number of small tumors currently detected, there is no evidence that perineural invasion should influence the decision on preservation of the nerve during radical prostatectomy.
EDITORIAL COMMENT
The importance of perineural invasion (PNI) in prostate biopsies remains controversial in the literature. The studies published since 1993 have shown an incidence of PNI variable from 11% to 38% significantly related to unfavorable histological features, specially extra-prostatic extension (EPE) and positive surgical margins (1, 2) . Some authors have shown a relationship between PNI and biochemical recurrence, and because of that, the description of the presence or absence of PNI in prostate biopsies plays a role in surgical pathology reports. The authors studied 264 patients, finding 18.2% of PNI related to EPE, higher Gleason score and seminal vesicles (SV) infiltration only for extensive tumors. However, they did not find any correlation between PNI and tumor progression. The most robust study was published recently by Loeb et al. (3) describing the Johns Hopkins experience with 1256 men submitted to radical prostatectomy, and they found a correlation between PNI with EPE and SV infiltration in multivariate analysis. In addition to the fact that tumor progression occurred in 10.5% of patients with PNI and in only 3.5% of patients without PNI, this aspect was not an independent risk factor for biochemical recurrence. Most importantly, it was not considered to decide nerve-sparing surgery. Since there is some agreement that PNI is related to aggressive pathologic features, we believe it is important that pathologists continue to describe the presence or absence of PNI to give the opportunity to surgeons, oncologists and radiotherapists to take this aspect in account to better plan patients' treatment.
(PNI). There are as many reports to suggest significance of PNI as there are reports that demonstrate no difference in patient outcomes. Specifically, can PNI predict preoperatively the presence of extracapsular extension (ECE) at the time of radical prostatectomy? Naturally, if this can be shown that a patient is at risk preoperatively for ECE, the surgeon may electively alter the technique to sacrifice part or all of the neurovascular bundle on the ipsilateral side of the disease. Additionally, this information may be useful in counseling patients pre-treatment regarding the pros and cons of various treatment options.
This report by Billis et al., does in fact demonstrate a subset of patients that have a significant risk of having a higher grade Gleason score, ECE and seminal vesicle involvement at the time of radical prostatectomy. Specifically, it was the group of patients in that more than 13.6% of linear (mm) malignant involvement was identified in the needle biopsy specimens. 25.8% of this cohort possessed PNI. Fortunately, regarding overall freedom from biochemical progression, there was no significant difference between those with and without PNI. Without question, better pretreatment patient selection will ultimately improve treatment outcomes. It is not uncommon to assume a patient has low risk criteria when in fact, they may harbor more advanced disease. In the future, clinicians will utilize more sophisticated biopsy techniques and apply known pathologic risk factors to decrease the risk of understaging prostate cancer.
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